Reginald Seeto
Net Worth
Last updated:
What is Reginald Seeto net worth?
The estimated net worth of Dr. Reginald Seeto is at least $16,554,559 as of 2 Oct 2023. He owns shares worth $5,548,719 as insider, has earned $6,060,640 from insider trading and has received compensation worth at least $4,945,200 in CareDx, Inc.
What is the salary of Reginald Seeto?
Dr. Reginald Seeto salary is $989,040 per year as Pres, Chief Executive Officer & Director in CareDx, Inc.
How old is Reginald Seeto?
Dr. Reginald Seeto is 53 years old, born in 1972.
What stocks does Reginald Seeto currently own?
As insider, Dr. Reginald Seeto owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| CareDx, Inc (CDNA) | Pres, Chief Executive Officer & Director | 479,164 | $11.58 | $5,548,719 |
What does CareDx, Inc do?
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Reginald Seeto insider trading
CareDx, Inc
Dr. Reginald Seeto has made 36 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 2,818 units of CDNA stock worth $19,484 on 2 Oct 2023.
The largest trade he's ever made was exercising 16,718 units of CDNA stock on 9 Jun 2021. As of 2 Oct 2023 he still owns at least 479,164 units of CDNA stock.
CareDx key executives
CareDx, Inc executives and other stock owners filed with the SEC:
- Dr. Peter Maag Ph.D. (58) Executive Director
- Dr. Reginald Seeto (53) Pres, Chief Executive Officer & Director
- Mr. Marcel Konrad (49) Senior Vice President of Fin. and Accounting & Corporation Controller
- Ms. Sasha King M.B.A. (39) Chief Marketing Officer & Franchise Head of Kidney Transplant